News for Healthier Living
ASH 2024: Antibody Shows Encouraging Results for Treating High-risk Follicular Lymphoma and Marginal Zone Lymphoma
ASH 2024 Presentations: Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers - follicular lymphoma and marginal zone lymphoma.
December 8, 2024
December 30 2024December 29 2024December 28 2024December 27 2024December 26 2024December 24 2024December 23 2024December 21 2024December 20 2024December 19 2024December 18 2024December 17 2024December 16 2024
|
|
|
|
|